Press Releases - Bristol Myers Squibb
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio. March 15, 2024. FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s …
Corporate news details - Bristol Myers Squibb
Sep 9, 2022 · Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first …
Bristol Myers Squibb - Bristol Myers Squibb Completes Acquisition …
Mar 18, 2024 · Bristol Myers Squibb will provide an update to its financial outlook when it reports first quarter 2024 results on April 25, 2024. Advisors. Gordon Dyal & Co. and Citi are serving …
Bristol Myers Squibb - Bristol Myers Squibb Adds Premier ...
Dec 26, 2023 · Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio. Transaction Brings RayzeBio’s Differentiated Actinium-Based …
Corporate news details - Bristol Myers Squibb
Jun 24, 2022 · Bristol Myers Squibb: Creating a Better Future for People with Cancer. Bristol Myers Squibb is inspired by a single vision—transforming patients’ lives through science. The …
Bristol Myers Squibb Announces Leadership Transition Plan
Apr 26, 2023 · NEW YORK-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that Giovanni Caforio, MD, Chairman of the Board and Chief Executive Officer, …
Bristol Myers Squibb - Bristol Myers Squibb to Acquire Turning …
Jun 3, 2022 · Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company. Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next …
Corporate news details - Bristol Myers Squibb
Oct 8, 2023 · Through this acquisition, Bristol Myers Squibb will add KRAZATI, an important lung cancer medicine, to its commercial portfolio. The company gains access to several promising …
Bristol Myers Squibb - Bristol Myers Squibb Reports Third Quarter ...
Oct 31, 2024 · Bristol Myers Squibb recently achieved several important clinical and regulatory milestones, including the U.S. approval of Cobenfy and the disclosure of long-term …
Corporate news details - Bristol Myers Squibb
Jan 23, 2024 · Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc. ® (“Mirati”). With the completion of the …